Alexion Pharmaceuticals Inc (ALXN)

ALXN (NASDAQ:Drugs) EQUITY
$125.80
pos +0.00
+0.00%
Today's Range: 125.34 - 127.98 | ALXN Avg Daily Volume: 1,956,600
Last Update: 07/22/16 - 4:00 PM EDT
Volume: 0
YTD Performance: -34.05%
Open: $0.00
Previous Close: $127.30
52 Week Range: $110.56 - $205.29
Oustanding Shares: 224,020,164
Market Cap: 28,517,766,877
6-Month Chart
TheStreet Ratings Grade for ALXN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 12 13 13 13
Moderate Buy 2 1 1 1
Hold 4 4 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.53 1.47 1.55 1.55
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 202.06
Price Earnings Comparisons:
ALXN Sector Avg. S&P 500
202.06 175.00 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-20.93% -38.98% 11.52%
GROWTH 12 Mo 3 Yr CAGR
Revenue 16.60 1.30 0.32
Net Income -78.00 -0.40 -0.17
EPS -79.50 -0.50 -0.20
Earnings for ALXN:
EBITDA 0.86B
Revenue 2.60B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $0.91 $1.10 $4.06 $5.72
Number of Analysts 1 1 1 1
High Estimate $0.91 $1.10 $4.06 $5.72
Low Estimate $0.91 $1.10 $4.06 $5.72
Prior Year $1.13 $0.93 $4.55 $4.06
Growth Rate (Year over Year) -19.47% 18.28% -10.77% 40.89%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands

bullishAlexion upgraded at Credit Suisse

Jul 11, 2016 | 7:57 AM EDT
ALXN was upgraded from Neutral to Outperform, Credit Suisse said. Valuation call, based on a $165 price target.
By

James "Rev Shark" DePorre

 | Jun 8, 2016 | 7:11 AM EDT

Too many turn bearish too quickly just because they can't find any entry points.

By

Bob Byrne

 | Jun 8, 2016 | 7:00 AM EDT

Big move for biotechs isn't pleasant.

By

Real Money

 | Jun 7, 2016 | 12:37 PM EDT

U.S. indices are up as oil continues its climb past $50 a barrel.

bullishAlexion upgraded at BMO

Apr 29, 2016 | 7:18 AM EDT

ALXN was upgraded to Outperform, BMO Capital said. $168 price target. Sell-off after earnings has created a buying opportunity.

By

Tony Owusu

 | Apr 28, 2016 | 8:34 AM EDT

Crude prices were also falling following the BOJ's decision to keep its monetary policy unchanged. 

By

Bruce Kamich

 | Feb 8, 2016 | 1:32 PM EST

The next potential support levels are the $120 and $100 areas from 2013.

By

Jared Woodard

 | Nov 30, 2015 | 11:50 AM EST

ILMN's three-month at-the-money implied volatility is at about the median level.

bullishAlexion upgraded at Morgan Stanley

Oct 2, 2015 | 7:50 AM EDT

ALXN was upgraded to Overweight, Morgan Stanley said. $211 price target. Orphan drugs should not face pricing concerns and the company has significant pipeline catalysts. 

By

Jim Cramer

 | May 18, 2015 | 3:24 PM EDT

Acquisitions cut into overabundance of companies.

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.